Literature DB >> 9419183

Enhanced control of an outbreak of Mycoplasma pneumoniae pneumonia with azithromycin prophylaxis.

J D Klausner1, D Passaro, J Rosenberg, W L Thacker, D F Talkington, S B Werner, D J Vugia.   

Abstract

There are currently no recommended epidemic-control measures for Mycoplasma pneumoniae pneumonia outbreaks in closed communities. Previous studies have suggested the usefulness of chemoprophylaxis administered to close contacts of case-patients. To evaluate the effectiveness of various epidemic-control measures during an institutional outbreak, an observational study was undertaken during a very large outbreak of M. pneumoniae pneumonia at a facility for developmentally disabled residents (n = 142 cases). Control measures evaluated included no control, standard epidemic-control measures, and targeted azithromycin prophylaxis (500 mg on day 1, 250 mg/day on days 2-5) plus standard epidemic-control measures. The combined use of azithromycin prophylaxis and standard epidemic-control measures was associated with a significant reduction in the secondary attack rate. This study suggests that the addition of antibiotic prophylaxis to standard epidemic-control measures can be useful during institutional outbreaks of M. pneumoniae pneumonia.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9419183     DOI: 10.1086/513818

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Evaluation of three real-time PCR assays for detection of Mycoplasma pneumoniae in an outbreak investigation.

Authors:  Jonas M Winchell; Kathleen A Thurman; Stephanie L Mitchell; W Lanier Thacker; Barry S Fields
Journal:  J Clin Microbiol       Date:  2008-07-09       Impact factor: 5.948

2.  Analysis of complement fixation and commercial enzyme immunoassays for detection of antibodies to Mycoplasma pneumoniae in human serum.

Authors:  W L Thacker; D F Talkington
Journal:  Clin Diagn Lab Immunol       Date:  2000-09

3.  Development of a genomics-based PCR assay for detection of Mycoplasma pneumoniae in a large outbreak in New York State.

Authors:  A L Waring; T A Halse; C K Csiza; C J Carlyn; K Arruda Musser; R J Limberger
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

Review 4.  Mycoplasma pneumoniae and its role as a human pathogen.

Authors:  Ken B Waites; Deborah F Talkington
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

5.  Detection of macrolide resistance in Mycoplasma pneumoniae by real-time PCR and high-resolution melt analysis.

Authors:  Bernard J Wolff; W Lanier Thacker; Stephanie B Schwartz; Jonas M Winchell
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

6.  An outbreak of Mycoplasma pneumoniae caused by a macrolide-resistant isolate in a nursery school in China.

Authors:  Yong Wang; Shaofu Qiu; Guang Yang; Lixue Song; Wenli Su; Yuanyong Xu; Leili Jia; Ligui Wang; Rongzhang Hao; Chuanfu Zhang; Jingmei Liu; Xiuping Fu; Jinrong He; Jingshan Zhang; Zhenjun Li; Hongbin Song
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

7.  Applying network theory to epidemics: control measures for Mycoplasma pneumoniae outbreaks.

Authors:  Lauren Ancel Meyers; M E J Newman; Michael Martin; Stephanie Schrag
Journal:  Emerg Infect Dis       Date:  2003-02       Impact factor: 6.883

8.  Chlamydia Species and Mycoplasma pneumoniae.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.663

9.  Polymerase chain reaction is superior to serology for the diagnosis of acute Mycoplasma pneumoniae infection and reveals a high rate of persistent infection.

Authors:  Anna C Nilsson; Per Björkman; Kenneth Persson
Journal:  BMC Microbiol       Date:  2008-06-11       Impact factor: 3.605

Review 10.  A Compendium for Mycoplasma pneumoniae.

Authors:  Gretchen L Parrott; Takeshi Kinjo; Jiro Fujita
Journal:  Front Microbiol       Date:  2016-04-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.